-
Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update
13 Aug 2025 20:05 GMT
… Cyclacel® are trademarks of Cyclacel Pharmaceuticals, Inc. SOURCE:
Cyclacel Pharmaceuticals, Inc.
CYCLACEL PHARMACEUTICALS, INC.
CONSOLIDATED STATEMENTS … ,316
)
(3,669
)
Income tax benefit
(2
)
412
Net loss
(1 …
-
CYCLACEL PHARMACEUTICALS HIGHLIGHTS PRECLINICAL DATA SHOWING THAT CANCER OF THE BILIARY TRACT IS SENSITIVE TO PLOGOSERTIB
04 Aug 2025 22:50 GMT
… with DNAJ-PKAc fusions, may benefit from treatment with plogosertib. … five dosing schedules. Clinical benefit was observed in patients with … Cyclacel® are trademarks of Cyclacel Pharmaceuticals, Inc. SOURCE:
Cyclacel Pharmaceuticals, Inc. 1 Yoojin Jeong …
-
CYCLACEL PHARMACEUTICALS COMMENTS ON RECENT STOCK PRICE VOLATILITY
16 Jul 2025 13:00 GMT
… ) the possibility that other anticipated benefits of the proposed transaction will … request to Cyclacel Pharmaceuticals, Inc., at ir@cyclacel.com. Contacts Cyclacel Pharmaceuticals, Inc.
Datuk …
-
CYCLACEL PHARMACEUTICALS HIGHLIGHTS PUBLICATION OF PRECLINICAL DATA SHOWING THAT PLOGOSERTIB IS ACTIVE IN A HARD-TO-TREAT SUBTYPE OF LIVER CANCER
07 Jul 2025 10:00 GMT
… with DNAJ-PKAc fusions, may benefit from treatment with plogosertib. … five dosing schedules. Clinical benefit was observed in patients with … Cyclacel® are trademarks of Cyclacel Pharmaceuticals, Inc. SOURCE:
Cyclacel Pharmaceuticals, Inc. 1 Chan M …
-
CYCLACEL PHARMACEUTICALS ANNOUNCES AMENDMENT TO EXCHANGE AGREEMENT
07 Jul 2025 10:00 GMT
… ) the possibility that other anticipated benefits of the proposed transaction will … request to Cyclacel Pharmaceuticals, Inc., at ir@cyclacel.com. Contacts Cyclacel Pharmaceuticals, Inc.
Datuk …
-
CYCLACEL PHARMACEUTICALS REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
15 May 2025 04:50 GMT
… cyclacel.com © Copyright 2025 Cyclacel Pharmaceuticals, Inc. All Rights … trademarks of Cyclacel Pharmaceuticals, Inc. SOURCE:
Cyclacel Pharmaceuticals, Inc. CYCLACEL PHARMACEUTICALS, INC.
… 81
)
(4,300
)
Income tax benefit
-
1,354
Net …
-
CYCLACEL PHARMACEUTICALS, INC. ANNOUNCES EXECUTION OF SHARE EXCHANGE AGREEMENT TO MAKE FITTERS SDN. BHD. ITS WHOLLY-OWNED SUBSIDIARY TO ACCELERATE GROWTH AND STOCKHOLDER VALUE
06 May 2025 10:00 GMT
… combined company or the expected benefits of the proposed Transaction or … ) failure to realize the anticipated benefits of the proposed Transaction; (iv … and Cyclacel® are trademarks of Cyclacel Pharmaceuticals, Inc. SOURCE:
Cyclacel Pharmaceuticals, Inc.
-
Cyclacel Pharmaceuticals Reports Fourth Quarter Financial Results and Provides Business Update
02 Apr 2025 20:05 GMT
… of Cyclacel Pharmaceuticals, Inc. SOURCE:
Cyclacel Pharmaceuticals, Inc.
CYCLACEL PHARMACEUTICALS, …
)
(25,551
)
Income tax benefit
(1,194
)
422
… 75
)
CYCLACEL PHARMACEUTICALS, INC.
CONSOLIDATED BALANCE SHEET
(In …
-
Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update
12 Nov 2024 21:45 GMT
… Cyclacel® are trademarks of Cyclacel Pharmaceuticals, Inc. SOURCE: Cyclacel Pharmaceuticals, Inc.
CYCLACEL PHARMACEUTICALS, INC.
CONSOLIDATED STATEMENTS … ,167
)
(6,700
)
Income tax benefit
210
668
Net loss
(1 …
-
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q2 2024 Earnings Call Transcript
15 Aug 2024 13:28 GMT
… from an unselected population.
Clinical benefit was observed in heavily pre … weeks. In addition, clinical benefit was reported in two patients … day. Goodbye.
Follow Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC) Follow Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC …
About
© 1995-2025